Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,120Revenue $M1.1Net Margin (%)-880.1Z-Score37.2
Enterprise Value $M1,053EPS $-1.2Operating Margin %-1,081.3F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,080.1Higher ROA y-yY
Price/Book15.910-y EBITDA Growth Rate %0Quick Ratio10.9Cash flow > EarningsY
Price/Sales3095-y EBITDA Growth Rate %0Current Ratio10.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-48.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M28.0ROI % (ttm)-59.8Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJean-Marie Eveillard 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 37.2110%Add 28.35%1,161,805
NLNKJean-Marie Eveillard 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 37.21109%Add 21.32%778,354
NLNKJean-Marie Eveillard 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 37.21137%Add 95.04%641,554
NLNKJean-Marie Eveillard 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 37.21208%New holding, 328939 sh.328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NLNK - CALLJean-Marie Eveillard 2014-09-3011,7600.040.02
NLNK Jean-Marie Eveillard 2014-09-301,257,6194.50.07-3.78%
Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Link Charles J. Jr.Chairman of the Board and CEO 2014-12-04Sell20,000$37.84-12.53view
HENNEMAN JOHN B IIIEVP, CFO 2014-11-25Buy5,000$34.35-3.64view
Link Charles J. Jr.Chairman of the Board and CEO 2014-11-10Sell20,000$32.940.49view
LINK GORDON H JRCFO 2014-10-24Sell2,500$40.39-18.05view
Ramsey William J.Quality Assurance Officer 2014-10-22Sell10,000$40-17.25view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-22Sell25,000$40.26-17.78view
Ramsey William J.Quality Assurance Officer 2014-10-16Sell5,000$3010.33view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-06Sell20,000$22.7245.69view
Ramsey William J.Quality Assurance Officer 2014-10-01Sell2,500$23.2542.37view
Link Charles J. Jr.Chairman of the Board and CEO 2014-09-05Sell20,000$25.6828.89view

Press Releases about NLNK :

    Quarterly/Annual Reports about NLNK:

    News about NLNK:

    Articles On GuruFocus.com
    NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

    More From Other Websites
    Human trial of experimental Merck Ebola vaccine is suspended Dec 11 2014
    Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Dec 11 2014
    Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Dec 11 2014
    $300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Dec 11 2014
    $300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Dec 11 2014
    NewLink Genetics Sinks On Temporary Halt Of Ebola Trial Dec 11 2014
    NewLink Ebola Shot Test Halted in Geneva on Side Effect Dec 11 2014
    What We're Trading Dec 11 2014
    One shot or two? Many questions unresolved in Ebola vaccine race Dec 11 2014
    No serious side effects in Merck/Newlink Ebola vaccine test Dec 02 2014
    No serious side effects in Merck/Newlink Ebola vaccine test Dec 02 2014
    HTML PDF Dec 01 2014
    American Airlines, Stone Energy, GlaxoSmithKline, Merck and NewLink Genetics highlighted as Zacks... Dec 01 2014
    Canada to deploy military health staff to Sierra Leone in Ebola fight Nov 27 2014
    Analyst: NewLink deal a 'boost' for Ebola vaccine Nov 26 2014
    Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014
    Merck Obtains Rights to Ebola Vaccine Nov 24 2014
    Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational... Nov 24 2014
    Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014
    Merck to Collaborate With NewLink on Experimental Ebola Vaccine Nov 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK